Plain-English translation of NCT06776770 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new drug called combined with two chemotherapy medications (capecitabine and oxaliplatin) to treat advanced or metastatic stomach cancer. The study has two phases: first, researchers will test what dose is safe and how well patients tolerate the medication; then, they will see how effective this combination is at shrinking tumors in patients with gastric or gastroesophageal junction cancer.
Currently, there are limited treatment options for patients with advanced stomach cancer who have never received chemotherapy before. This medication is designed to help the immune system fight cancer cells, and researchers believe combining it with existing chemotherapy drugs may be more effective than chemotherapy alone.
You likely qualify if…
You likely don't qualify if…
You would receive intravenous infusions of the new medication combined with chemotherapy pills and IV chemotherapy on a repeating 3-week cycle. In Phase 1, the study determines the safest and most effective dose; in Phase 2, patients receive the finalized dose. Throughout the trial, you'll have regular blood tests and imaging scans to check how well the treatment is working and to monitor for any side effects. The trial expects to enroll about 52 patients total.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
China